Antibodies
15 September 2015
BeyondSpring Announces Planned Start of Phase I Investigator-Initiated Trial of Plinabulin Plus Nivolumab, Enters Immuno-Oncology Space15 September 2015
Glenmark’s Bi-Specific Antibody – GBR 1302 to Enter Phase I Trials15 September 2015
Baxalta Files for U.S. Approval of Investigational 20% Immunoglobulin Subcutaneous (IGSC) Treatment for Primary Immunodeficiency (PI)12 September 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)11 September 2015
AbbVie’s HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa10 September 2015
Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous Non Small Cell Lung Cancer and Mesothelioma10 September 2015
Janssen Submits Marketing Authorisation Application for daratumumab for European Patients With Heavily Pre-treated Multiple Myeloma8 September 2015
Immunomedics Reports Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers8 September 2015
Biogen Enrolls First Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer’s Disease8 September 2015
Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea4 September 2015
Glenmark’s Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe4 September 2015
Chugai’s Bispecific Antibody “ACE910” for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA2 September 2015
ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome2 September 2015
Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide1 September 2015
Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 201531 August 2015
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports